Community-Based Lifestyle Modification of Cardiovascular Disease Risks in Middle-Aged Japanese: A 27-Month Update

Fujii, Hiroko; Muto, Takashi; Haruyama, Yasuo; Nakade, Makiko; Kobayashi, Emiko; Ishisaki, Kaori; Yamasaki, Akira

doi:10.1620/tjem.220.307

Cited by 13 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study was one part of the project, which was implemented in Soka City in Saitama Prefecture, Japan, with a population of about 233,000 [20,21]. …”

Section: Methodsmentioning

confidence: 99%

Evaluation of a community intervention program in Japan using Framingham risk score and estimated 10-year coronary heart disease risk as outcome variables: a non-randomized controlled trial

et al. 2013

Self Cite

View full text Add to dashboard Cite

BackgroundCommunity-based programs are being widely adopted in the struggle to prevent cardiovascular diseases. No study has been conducted in Japan to evaluate the effects of a community-based health promotion program by using the Framingham risk score and 10-year CHD risk as outcome variables. The aim of the present study was to assess the effects of a program involving 6-month intervention and 18-month follow-up using such outcomes.MethodsParticipants (n = 1,983, 39.5% women, mean age 63.4 years) were selected for the study in 2008. Of these 1,983, 347 (42.4% women) subjects received the 6-month intervention. The intervention included individual counseling and group sessions, among others. After 18 months, 1,278 participants (intervention group: 238, control group: 1,040) were followed up. Changes in the Framingham risk score and 10-year coronary heart disease (CHD) risk were evaluated. ANCOVA and multiple logistic models adjusted for baseline value, age, sex and intervention times were used.ResultsThe results showed that the differences in the Framingham risk score and mean 10-year CHD risk were significant in the intervention group compared with the control group after 6-month follow-up (-0.46 and -1.12, respectively) and were also significant after 18-month follow-up (-0.39 and -0.85, respectively). The proportion of those with intermediate 10-year CHD risk (> = 10%) was significantly lower at 6 months (OR 0.30, 95% CI 0.12-0.74) and at 18 months (OR 0.41, 95% CI 0.19-0.92).ConclusionsThe six-month intervention program effectively decreased estimated 10-year CHD risk and the effects were still present at 18-month follow-up.Trial registrationUMIN-CTR: UMIN000008163

show abstract

“…This study was one part of the project, which was implemented in Soka City in Saitama Prefecture, Japan, with a population of about 233,000 [20,21]. …”

Section: Methodsmentioning

confidence: 99%

Evaluation of a community intervention program in Japan using Framingham risk score and estimated 10-year coronary heart disease risk as outcome variables: a non-randomized controlled trial

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Plasma glucose levels were measured by glucose oxidase method, HbA1c levels were by HPLC method (Arkray Inc. Kyoto). At the initiation of sitagliptin, the evaluations of life-style were made according to the check list modified for the present study [10] as below. changes of blood glucose level and body weight were compared among these 3 groups to explore any factors to predict the efficacy of sitagliptin before initiation of this drug.…”

Section: Protocolmentioning

confidence: 99%

Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan

et al. 2012

View full text Add to dashboard Cite

“…To date, most of clinical information related to this therapeutic class have been available from evi-a questionnaire with the modified check lists [13,14] (Supplementary Table 1).…”

mentioning

confidence: 99%

Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy

et al. 2016

View full text Add to dashboard Cite

THE BODY MASS INDEX (BMI) of Japanese patients with type 2 diabetes mellitus (T2DM) has been progressively increasing, with recent reports indicating that the current average BMI is now 25.0 kg/m 2 [1]. Although the average BMI of Asian patients with T2DM is apparently low, these patients characteristically tend to possess a large amount of visceral adipose tissue (VAT) [2], presumably leading to the increase of metabolic complications associated with their T2DM.Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve glycaemia and reduce body weight in patients with T2DM by enhancing urinary glucose excre- Abstract. To investigate if ipragliflozin, a novel sodium-glucose co-transporter 2 inhibitor, alters body composition and to identify variables associated with reductions in visceral adipose tissue in Japanese patients with type 2 diabetes mellitus. This prospective observational study enrolled Japanese participants with type 2 diabetes mellitus. Subjects were administered ipragliflozin (50 mg/day) once daily for 16 weeks. Body composition, visceral adipose tissue volume and plasma variables were measured at 0, 8, and 16-weeks. The subjects' lifestyle habits including diet and exercise were evaluated at baseline and 16 weeks. The primary endpoint was defined as the decrease of visceral adipose tissue mass. Twenty-four of 26 enrolled participants completed the study. The visceral adipose tissue decreased significantly (110 ± 33 to 101 ± 36 cm 2 , p = 0.005) as well as other parameters for metabolic insufficiency including hemoglobin A1c. Seventyone % of the total body weight reduction (-2.49 kg) was estimated by a decrease in fat mass (-1.77 kg), and the remaining reduction (22%) by water volume (-0.55 kg). A minor but significant reduction in the skeletal muscle index was also observed. Correlation analyses were performed to identify variables associated with changes in visceral adipose tissue and the only significant variable identified was diet therapy (Spearman's r = -0.416, p = 0.043). Ipragliflozin significantly decreased visceral adipose tissue, and improved parametres for metabolic dysfunction. Adequate diet therapy would be necessary to induce and enhance the therapeutic merit.Key words: Diet therapy, Ipragliflozin, Visceral adipose tissue tion [3][4][5]. These characteristics are suitable for treatment strategy for obese patients. While the SGLT2-associated weight loss is mainly caused by a reduction of fat mass, reduced lean muscle mass due to an increase in compensatory gluconeogenesis has been assumed in response to increased glucose excretion. Accordingly, sarcopenia related with SGLT2 inhibitor administration has been one of the major concerns in daily clinical practice [6][7][8], as well as compensatory hyperphagia associated with increased glucose excretion [9][10][11].Given the significantly lower average BMI of Asian patients with T2DM as compared to that found in Western populations, it is important to evaluate potential changes in body composition (VAT and lean mass) associated with SGL...

show abstract

Community-Based Lifestyle Modification of Cardiovascular Disease Risks in Middle-Aged Japanese: A 27-Month Update

Cited by 13 publications

References 21 publications

Evaluation of a community intervention program in Japan using Framingham risk score and estimated 10-year coronary heart disease risk as outcome variables: a non-randomized controlled trial

Evaluation of a community intervention program in Japan using Framingham risk score and estimated 10-year coronary heart disease risk as outcome variables: a non-randomized controlled trial

Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan

Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy

Contact Info

Product

Resources

About